ARTICLE | Company News
Nanogen up on CHF test approval
March 30, 2006 2:14 AM UTC
NGEN gained $0.48 (18%) to $3.18 on Wednesday after the company received 510(k) clearance from FDA for the company's StatusFirst CHF NT-proBNP test to diagnose congestive heart failure (CHF). The immu...